Pacific Biosciences of California Inc. (NASDAQ:PACB) shares, rose in value on Wednesday, 05/24/23, with the stock price down by -4.94% to the previous day’s close as strong demand from buyers drove the stock to $11.94.
Actively observing the price movement in the last trading, the stock closed the session at $12.56, falling within a range of $11.63 and $12.30. The value of beta (5-year monthly) was 1.67. Referring to stock’s 52-week performance, its high was $14.20, and the low was $3.85. On the whole, PACB has fluctuated by 16.94% over the past month.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
With the market capitalization of Pacific Biosciences of California Inc. currently standing at about $2.98 billion, investors are eagerly awaiting this quarter’s results, scheduled for Aug 01, 2023 – Aug 07, 2023. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.32, which is expected to increase to -$0.25 for fiscal year -$1.26 and then to about -$1.04 by fiscal year 2024. Data indicates that the EPS growth is expected to be 10.00% in 2024, while the next year’s EPS growth is forecast to be 17.50%.
Analysts have estimated the company’s revenue for the quarter at $40.5 million, with a low estimate of $38.04 million and a high estimate of $42.8 million. According to the average forecast, sales growth in current quarter could jump up 14.20%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2024, the company’s y-o-y revenues would reach $179.02 million, representing an increase of 39.50% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that PACB’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 100% Buy.
10 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 5 analyst(s), 5 recommend it as a Buy and 0 called the PACB stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Overweight.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of PACB currently trading nearly 0.37% and 9.75% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 51.66, while the 7-day volatility ratio is showing 5.64% which for the 30-day chart, stands at 6.06%. Furthermore, Pacific Biosciences of California Inc. (PACB)’s beta value is 1.65, and its average true range (ATR) is 0.70. The company’s stock has been forecasted to trade at an average price of $13.80 over the course of the next 52 weeks, with a low of $12.00 and a high of $17.00. Based on these price targets, the low is -0.5% off current price, whereas the price has to move -42.38% to reach the yearly target high. Additionally, analysts’ median price of $13.50 is likely to be welcomed by investors because it represents a decrease of -13.07% from the current levels.
A comparison of Pacific Biosciences of California Inc. (PACB) with its peers suggests the former has fared considerably weaker in the market. PACB showed an intraday change of -4.94% in last session, and over the past year, it grew by 108.01%%. In comparison, Thermo Fisher Scientific Inc. (TMO) has moved lower at -2.74% on the day and was down -8.01% over the past 12 months. On the other hand, the price of Standard BioTools Inc. (LAB) has risen 1.21% on the day. The stock, however, is off -3.46% from where it was a year ago. Additionally, there is a gain of 4.05% for Illumina Inc. (ILMN) in last trading while the stock has seen an overall depriciation of -13.23%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.73%. Meanwhile, the Dow Jones Industrial Slipped by -0.77%.
Data on historical trading for Pacific Biosciences of California Inc. (NASDAQ:PACB) indicates that the trading volumes over the past 10 days have averaged 3.45 million and over the past 3 months, they’ve averaged 3.67 million. According to company’s latest data on outstanding shares, there are 242.03 million shares outstanding.
Nearly 0.80% of Pacific Biosciences of California Inc.’s shares belong to company insiders and institutional investors own 88.90% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 24.18 million shares as on May 14, 2023, resulting in a short ratio of 7.51. According to the data, the short interest in Pacific Biosciences of California Inc. (PACB) stood at 9.67% of shares outstanding as of May 14, 2023; the number of short shares registered in Apr 13, 2023 reached 27.18 million. The stock has risen by 45.97% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PACB stock heading into the next quarter.
